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Background: HIPEC with cisplatin in 
recurrent and advanced ovarian cancer 
(AOC) improves survival, but renal 
toxicity is common, even with renal 















carboplatin HIPEC for recurrent and AOC. 
Methods: Retrospective analysis of a 
cytoreductive surgery (CRS) /HIPEC registry 
was performed on recurrent and AOC 
patients treated between 2012-2018 with and 
without HIPEC. HIPEC with carboplatin 
(600-800 mg/mM2) was delivered for 90 
minutes at 41-42 C. Peritoneal Cancer Index 
(PCI), Completeness of Cytoreduction 
(CC)-score, nephrotoxicity by RIFLE score, 
thrombocytopenia, pancytopenia, length of 
stay (LOS), progression free survival (PFS), 
overall survival (OS), peritoneal relapse 
and all relapse events were collected and 
compared from the date of surgery. 
Results: A total of 34 recurrent and AOC 
patients had CRS, 21 treated with HIPEC. 
Mean PCI for CRS and CRS/HIPEC was 23 
and 22 respectively. 95% HIPEC and 100% 
no HIPEC had R0/R1/R2a. 9% developed 
>grade 1 AKI. Thrombocytopenia (platelet 
< 75K) occurred in 23% of HIPEC patients. 
LOS was 9.5 days for both groups. Post-CRS 
OS was 15 vs. 56 months for CRS vs. CRS/
HIPEC, p<0.01. There was no difference 










was 69% for CRS vs 19% for CRS/HIPEC, 
p<0.01. 
Conclusion: This data demonstrates that 
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to cisplatin without the nephrotoxicity. 







be attributable to peritoneal disease control 
and peritoneal relapse free survival may be 
a viable endpoint in future HIPEC clinical 
trials. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.031
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Background: MSLT established SLN 
management in extremity/trunk melanoma, 
demonstrating a 16% positive SLN (+SLN) 
rate and 14% positive non-SLN rate (+NSLN) 










Results of MSLT guide H&N melanoma but 
H&N only represented 13% of patients in 
MSLT II. This project explored the validity 
of observations reported in MSLT II in H&N 
melanoma.




with SLN injection and 108 SLN dissections 
were performed. Complication rates, T-stage, 
rates of +SLN, +NSLN in CLND were 
calculated, as well as death due to disease 
(DOD), progression free survival (PFS), along 
with rates of local (LR), nodal (LNR), and 
systemic (SR) recurrence. 
Results: T-stage was 41% IB, 23% IIA, 28% 
IIB, 8% IIC. Nerve complication was 4% 
for SLN and 11% for CLND. – SLN group 
survival is 93% compare to survival of 70% 
for +SLN group with median follow-up 
of 40 months. Rate of +SLN was 29% and 
+NSLN rate for CLND was 50%. Patients 
with positive SLN but did not undergo CLND 
(+SLNBx only) has surprisingly lower rate 
of LR, LNR, SR, and DOD when compared 
to patients with positive SLN who underwent 
CLND (CLND group). (Table 1.)
Conclusion: +SLN rate was 2-fold higher and 
+NSLN following CLND was 3-fold higher 
in H&N melanoma. Local regional recurrence 
rates were higher for CLND compared to 
SLNB+ only. These results support nodal 
Table 1.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) group demonstrates increased overall survival 
(OS), reduced rate of peritoneal relapse, and similar overall relapse rate when compared with non-
HIPEC group. Upfront HIPEC is associated with lower peritoneal relapse rate when compared with 
HIPEC performed after disease recurrence. 
GROUP # OSCRS 
months




ALL 34 34 - - - -
No HIPEC 13 20 73% 0% !" 87%
HIPEC 21 $ 42% 38% 19% 79%
HIPECrecurrent 9 $ 33% 15% 33% 92%
HIPECupfront 12 $ 23% 58% 8% 67%
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*Names in bold type indicate presenting author.
behavior and failure patterns in H&N may 
be different from trunk/extremity, supporting 
consideration of dedicated H&N trial. 
https://doi.org/10.32873/unmc.dc.gmerj.2.1.032
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and increases risk for encephalopathy.1,2 
Thiamine supplementation for patients with 







hypothesized that thiamine supplementation 
in hospitalized patients with encephalopathy 
would decrease their length of stay (LOS).
Methods: Adults (age >19 years) with index 
admission to UNMC between 1/1/2017 and 
12/31/2017, hospital stay of 3-30 days, and 









health record data access core. Primary 
outcome was hospital LOS, which we log-
transformed due to skewness. Model adjusted 
mean log LOS estimates were exponentiated 
to obtain geometric means. Patients in 
the Thiamine group received at least one 
dose of supplemental thiamine (including 
multivitamins). A general linear model was 
used to evaluate the association between log 






met the above criteria. Table 1 describes 
the cohort demographics and clinical 
characteristics. After adjusting for potential 
confounding variables (denoted in Table 1), 
the mean log LOS was 1.95 for the Thiamine 
group and 1.63 for the No Thiamine group (p 
<0.0001). 
Table 1.
+SLN group demonstrates higher rate of local (LR), nodal (LNR), and systemic (SR) recurrence, as 
well as higher rate of death due to disease (DOD) when compared with -SLN group. Within +SLN 
group, patients who underwent complete lymph node dissection (CLND) surprisingly have higher rate 
of LR, LNR, SR, and DOD. 
Completed SLNBx  
(N= 108)
LR % LNR % Local/Regional 
recurrence %
SR % Combined 
Sys/Nodal %
DOD % NED %











































Age (mean ± SD)* 66.5 ± 18.1 59.4 ± 15.5 <0.0001a
Gender* 0.0004
Female 67 (37.6) 423 (52.4)
Male 111 (62.4) 384 (47.6)
Race 0.47
Black 32 (18.4) 119 (14.8)
White 129 (74.1) 627 (78.1)
Other 13 (7.5) 57 (7.1)
Ethnicity 0.65
Hispanic 8 (4.5) 43 (5.3)
Not Hispanic 170 (95.5) 763 (94.7)
Work status  <0.0001
Disabled 44 (25.1) 166 (20.7)
Employed/Student/Retired 81 (46.3) 524 (65.3)
Not employed 50 (28.6) 112 (14.0)
Insurance status* 0.004
Insured 151 (84.8) 741 (91.8)
Not insured 27 (15.2) 66 (8.2)
Clinical Characteristics
Log (DRG weight) (mean ± SD) 0.43 ± 0.64 0.26 ± 0.53 0.001a
Alcohol use* 68 (51.9) 166 (26.0) <0.0001
PMH of malabsorption 20 (11.2) 115 (14.3) 0.29
PMH of GI disease 22 (12.4) 113 (14.0) 0.56
PMH of malnutrition* 46 (25.8) 167 (20.7) 0.13
PMH of cancer 40 (22.5) 220 (27.3) 0.19
PMH of GI surgery 28 (15.7) 98 (12.1) 0.19
Home use of loop diuretics 4 (2.2) 17 (2.1) 0.78b
Home use of PPIs 1 (0.6) 17 (2.1) 0.22b
Sepsis during hospital stay* 46 (25.8) 193 (23.9) 0.59
DKA during hospital stay* 27 (15.2) 72 (8.9) 0.01
Neurology service consulted* 57 (32.0) 141 (17.5) <0.0001
Outcomes
Log (Length of stay) (mean ± SD) 1.98 ± 0.70 1.60 ± 0.60 <0.0001a
Abbreviations: SD = standard deviation. DRG = 
diagnosis-related group. PMH = past medical history. 
GI = gastrointestinal. DKA = diabetic ketoacidosis. LOS 
= length of stay.
P-values from Chi-Square tests, unless otherwise 
	 
a P-values from t-test. 
b P-values from Fisher’s exact test. 
* Potential confounding variables that can contribute to 
log (LOS) via linear model.
Demographic information, clinical characteristics, 
and primary outcome were compared between the 
Thiamine group and No Thiamine group. 
